Welcome to our dedicated page for Celcuity news (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity stock.
Celcuity Inc. develops targeted oncology therapies as a clinical-stage biotechnology company, with news centered on gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor for solid tumors. Company updates frequently cover Phase 3 VIKTORIA-1 data in HR+/HER2- advanced breast cancer, including PIK3CA wild-type and mutant cohorts and combination regimens with fulvestrant and palbociclib.
Recurring announcements also address FDA regulatory submissions and review status for gedatolisib, publications and medical-meeting presentations, quarterly financial results, corporate updates, investor conference participation, and board governance changes.
Celcuity Inc. (Nasdaq: CELC), a biotechnology firm focused on developing companion diagnostics for cancer, announced that CEO Brian Sullivan will present at the B. Riley Oncology Investor Conference on January 21, 2021, at 1:00 pm ET. Attendees can register for the live webcast and participate in online one-on-one meetings with Mr. Sullivan. Following the event, a replay of the presentation will be available on Celcuity's website. The company’s CELsignia platform aims to improve cancer diagnostics and expand treatment options for patients.
Celcuity Inc. (NASDAQ:CELC) has announced a Phase II clinical trial collaboration with Massachusetts General Hospital and Puma Biotechnology to assess the efficacy and safety of NERLYNX and FASLODEX in HR-positive, HER2-negative metastatic breast cancer patients. The trial will utilize Celcuity's CELsignia HER2 Activity Test to identify eligible patients, with interim results expected in 12 to 15 months. Celcuity will cover patient-related costs, marking their first collaboration focusing on targeted therapies for this patient population. The trial aims to address resistance to anti-estrogen therapies.
Celcuity Inc. (NASDAQ:CELC) reported its third quarter results for 2020, revealing a net loss of $2.47 million or $0.24 per share, a decline from $1.98 million or $0.19 per share in Q3 2019. Operating expenses rose to $2.48 million from $2.09 million year-over-year, driven by increased R&D and G&A costs. The company holds $13.7 million in cash, expected to fund operations through 2021. Upcoming collaborations with pharmaceutical companies on cancer trials are progressing, with interim results from FACT-1 and FACT-2 trials anticipated in late 2021.
Celcuity Inc. (Nasdaq: CELC) has announced the release of its financial results for the third quarter of 2020 on November 9, 2020, after market close. A teleconference will follow at 4:30 p.m. ET to discuss these results. The company specializes in innovative cancer diagnostics through its CELsignia platform, which analyzes living tumor cells to identify new cancer sub-types that traditional diagnostics may miss. This advancement aims to improve patient outcomes and enhance targeted therapy definitions.
Celcuity Inc. (NASDAQ:CELC) will present at the LD 500 Investor Conference from September 1-4, 2020. CEO Brian Sullivan is scheduled to speak on September 2 at 11:00am ET on Track 1. The virtual presentation will be accessible via a live audio webcast, with an archived version available later. Celcuity focuses on developing next-generation diagnostics and therapeutic options for cancer patients through its innovative CELsignia platform. This conference provides a platform for one-on-one investor interactions to discuss the company's advancements.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter 2020 financial results, indicating a net loss of $2.20 million ($0.21 per share), up from $1.72 million ($0.17 per share) in Q2 2019. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Cash and cash equivalents stood at $15.4 million as of June 30, 2020, expected to fund operations through 2021. The company remains focused on advancing its CELsignia diagnostic tests and anticipates announcing new collaborations by year-end, despite COVID-19-related delays in clinical trials.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter financial results for 2020, highlighting a net loss of $2.20 million, or $0.21 per share. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Despite a cash burn rate remaining steady, cash and cash equivalents stood at $15.4 million as of June 30, expected to support operations through 2021. The company announced ongoing development of CELsignia tests and anticipates finalizing collaborations with pharmaceutical companies by year-end. Interim results from ongoing trials are expected in late 2021.